World population 7,900m (100% of possible total market)
Europe population 746m (9.5% of total market)
USA population 329m (4% of total market)
UK population 76m (1% of total market)
Status:
Avacta submitted, ahead of the 1 September 2021 deadline, all the information required for its AffiDX test to be validated under these regulations by the UK Health Security Agency, and the Company has paid the required fee. The Company awaits further notification from the UK Health Security Agency when it completes its review of the information supplied for the AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test.
Stated by Avacta:
The impact of suspension of sales in the UK as a result of the CTDA regulations coming into force will not have a material impact on the Company's anticipated financial outturn for the financial year ending 31 December 2021.
Many poorer nations have not vaccinated and LFTs will be important to protecting their citizens. There may be a dip today but, as stated by AS, this decision will not have a material impact.
Approval is in process and can happen at any time.
And we have the AVA6000 trials.
Russia has reported 1,163 new Covid-19 deaths, its highest one-day toll of the pandemic.
It comes amid a surge in cases that has resulted in officials reinstating some lockdown measures.
Deaths have set new records in nine of the past 11 days.
Russia will go into a national workplace shutdown for the first week of November.
Moscow reinstated partial lockdown measures on Thursday, with only essential shops like pharmacies and supermarkets permitted to stay open.
https://www.bbc.co.uk/news/live/uk-59087077
One in 50 people in England are estimated to have had Covid last week, the Office for National Statistics (ONS) says.
Its survey suggests that 1.3 million people in the UK tested positive last week, the highest number since records began.
Test, Test, Test
04 Aug 2021 (week 31)
Update on AffiDX® SARS-CoV-2 Antigen Lateral Flow Test
“Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms is pleased to announce that shipment of its AffiDX® SARS-CoV-2 antigen lateral flow test has now commenced.
The Company has recently appointed Calibre Scientific, a global distributor of diagnostic and life science products, as the first distributor for the test in the UK and European Union, and is progressing multiple commercial opportunities with distributors and end users in Europe, UK, Asia and elsewhere".
https://avacta.com/update-on-affidx-sars-cov-2-antigen-lateral-flow-test/
We are currently in week 43 so 12 weeks on from the above. It would be nice to have an update on LFT shipments.
A simple item in the News section of the Avacta website offering an indication of where the tests are going (UK, Europe, Asia), how many have shipped, (5m, 10m, 20m, etc) and where they are being used, (medical, tourism, aviation, etc).
Not sensitive, just a general update.
Just logged in to read the discussions.
There are a lot of green boxes.
LSE offers Reply / Recommend / Report Post.
Perhaps time for a fourth choice?
Possible, … Dislike / Reject / Frown
Would be good to get back to the subject matter and not the other nonsense.
LiveLearn posted
"NHS Test and Trace tests - which can be ordered for free - cannot be used for international travel, the government said"
When was it actually stated or written and by whom?
Not arguing, just interested, ... :-)
@LivenLearn
Where did the government say:
"NHS Test and Trace tests - which can be ordered for free - cannot be used for international travel, the government said"
If correct, reflects doubt in the performance of the current LFT's
Avacta LFT on LinkedIn
We're delighted to unveil the latest product photos of the AffiDX® SARS-CoV-2 antigen lateral flow test. Developed and manufactured in the UK, we're also proud that our cardboard kit box can be recycled after use.
https://www.linkedin.com/posts/avacta_supportingukbusiness-activity-6849293006965628931-zxPy
Oxford Nanopore
Company floated this week with unique IP.
Revenue for the first 6 months of the year £ 59m.
No profit/Loss = Loss of £ 44.4m.
Current Market Cap at £ 5bn.
Avacta
Sales currently low and operating at a loss.
Unique IP in AVA6000 and Affimers
Share price at £ 1.20
Share price at £ 4.00 = Market Cap at £ 1bn.
Not unrealistic and could be easily be higher.
Interesting times ahead.
For long term followers and share holders, the Avacta interim results were as expected.
AS upbeat about AVA6000 trials along with the new additions to the team. AVA6000 is a game changer and lifesaving product offering.
Avacta LFT detects Covid variants and offers exception performance. Manufacturing capacity is in place along with contract discussions. Professional use approved, HUA pending.
No horror stories so expect the share price to remain stable and climb as we receive RNS updates relating to the above. The price drop has been painful but it will recover over the coming months. We all believe in the science and Avacta's future.
Have a good weekend everyone.
Summary of an interesting article published today by Chris Rand at Business Marketing Online.
(https://www.bmon.co.uk/articles/)
Getting a new product launch right
“Many companies undermine their product launches by making it all about them, rather than the benefits to the customer. One of the biggest giveaways is simply the word ‘launch’. If the news is that the company is launching a product, it’s already taken the focus away from the product.
Whatever the significance of the new product, it’s important to remember what it’s all about. Often a product can be more important than the company launching it (especially with startups), and the launch will put the company on the map. But that’s even more reason to make it about the product. Nobody cares about a company they haven’t heard of.
Then there’s the timing. Bringing everything together is a tough task, but product launches can be wasted if the availability slips. Look at how brilliantly Apple tends to manage its iPhone launches, with the actual devices actually in the shops a week after the launch, as announced.”
The above can easily be applied to the Avacta LFT. Available through BioServ and Medusa 19.
HUA launch this week along with volume stocks to meet demand?